Sign inCreate account

Report workspace tools

NCT01096134COMPLETEDanonymous

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

Sponsor

Source record

Jhpiego

Phase

Source record

NA

Modality

AI-normalized

vaccine

Target

AI-normalized

HPV Vaccine (Gardasil)

Indication / condition

AI-normalized

Cervical Cancer

Intervention

Source record

HPV Vaccine (Gardasil)

Source & freshness

Source record

NCT ID

NCT01096134

Original source

ClinicalTrials.gov

Source last updated

Oct 12, 2015

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01096134

Title

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

Sponsor

Jhpiego

Status

COMPLETED

Phase

NA

Condition raw

Cervical Cancer

Condition normalized

Cervical Cancer

Modality raw

vaccine

Modality normalized

vaccine

Target raw

HPV Vaccine (Gardasil)

Target normalized

HPV Vaccine (Gardasil)

Interventions

HPV Vaccine (Gardasil)

Public preview

Source record

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines by integrating the HPV vaccine for girls ages 9-13 into already successful screening and treatment programs for mothers.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01096134

Status

COMPLETED

Phase

NA

Sponsor

Jhpiego

Executive brief

Investment-Ready Snapshot

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines by integrating the HPV vaccine for girls ages 9-13 into already successful screening and treatment programs for mothers.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 12, 2015
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01096134

Indication

Cervical Cancer

Modality

vaccine

Target

HPV Vaccine (Gardasil)

Intervention

HPV Vaccine (Gardasil)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.